PMID: 6215443Sep 1, 1982Paper

Fluvoxamine and chlorimipramine in endogenous depression

Journal of Affective Disorders
J E De Wilde, D Doogan

Abstract

Thirty patients were treated in a randomised double-blind efficacy study of fluvoxamine and chlorimipramine. The dose range for both drugs was 50-300 mg in divided daily doses. Mean daily doses were higher for fluvoxamine than chlorimipramine. Generally the baseline recordings were comparable for both drug groups. Fluvoxamine was superior to chlorimipramine in all the rating scales used without achieving statistical significance. Chlorimipramine, but not fluvoxamine, caused a significant decrease in blood pressure. There were no significant effects on ECG or laboratory variables. There was no significant relationship between plasma levels of either compound or metabolite and clinical response. Chlorimipramine exerted more unwanted effects than fluvoxamine. Autonomic effects of fluvoxamine were minimal in comparison with chlorimipramine. Chlorimipramine patients required more concurrent anxiolytic medication than fluvoxamine. Both drug groups required a significant amount of concurrent hypnotic medication.

References

Aug 1, 1977·British Journal of Pharmacology·V ClaassenP Placheta
Dec 15, 1977·European Journal of Pharmacology·P C WaldmeierL Maître
Dec 1, 1967·The British Journal of Social and Clinical Psychology·M Hamilton
Dec 1, 1980·Neuropharmacology·D P Doogan

❮ Previous
Next ❯

Citations

Dec 1, 1984·Journal of Affective Disorders·K R NortonE S Paykel
Jul 1, 1988·Journal of Affective Disorders·P L DelgadoG R Heninger
Mar 1, 1993·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·S KasperH J Möller
Feb 16, 2000·Pharmacology & Therapeutics·C Hiemke, S Härtter
Dec 1, 2001·Psychiatry Research·N UedaJ Nakamura
Jan 1, 1989·Psychological Medicine. Monograph Supplement·S J WarringtonM Lader
Apr 20, 1999·The American Journal of Forensic Medicine and Pathology·G W KunsmanP Rodriguez
Sep 15, 2005·Journal of Clinical Psychopharmacology·David RossiniRaffaella Zanardi
Oct 18, 2006·Bipolar Disorders·Susan L McElroyPaul E Keck
Sep 1, 2015·Neuroscience·R W Logan, C A McClung
Dec 5, 2009·Acta Psychiatrica Scandinavica·L TondoR J Baldessarini
Jan 1, 1990·Current Medical Research and Opinion·G GonellaU Ecari
Dec 12, 2012·Journal of Affective Disorders·Ross J BaldessariniLeonardo Tondo
Jan 7, 2015·The Journal of Toxicological Sciences·Yukiko Yamazaki-HashimotoAtsushi Sugiyama
Apr 3, 2003·Human Psychopharmacology·Shigeru Morishita, Seizaburo Arita
Jul 20, 2007·The Cochrane Database of Systematic Reviews·J R GeddesJ Boynton
Nov 30, 2018·Fundamental & Clinical Pharmacology·Xavier HumbertJoachim Alexandre
Jul 9, 2008·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Hikaru HoriJun Nakamura
Feb 1, 1997·The British Journal of Psychiatry : the Journal of Mental Science·M HotopfG Lewis
Mar 20, 2010·The Cochrane Database of Systematic Reviews·Ichiro M OmoriToshi A Furukawa
Aug 26, 1998·Therapeutic Drug Monitoring·S HärtterC Hiemke
Jan 1, 1985·Acta Pharmacologica Et Toxicologica·J Hyttel, J J Larsen
Mar 28, 1998·British Journal of Clinical Pharmacology·O SpigsetR Dahlqvist
Oct 19, 2001·CNS Drug Reviews·H Silver
Jan 1, 1983·British Journal of Clinical Pharmacology·J E De WildeJ S Wakelin

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bipolar Disorder

Bipolar disorder is characterized by manic and/or depressive episodes and associated with uncommon shifts in mood, activity levels, and energy. Discover the latest research this illness here.